"10.1371_journal.pone.0021225","plos one","2011-08-03T00:00:00Z","Gavin J Churchyard; Cecilia Morgan; Elizabeth Adams; John Hural; Barney S Graham; Zoe Moodie; Doug Grove; Glenda Gray; Linda-Gail Bekker; M Juliana McElrath; Georgia D Tomaras; Paul Goepfert; Spyros Kalams; Lindsey R Baden; Michelle Lally; Raphael Dolin; William Blattner; Artur Kalichman; J Peter Figueroa; Jean Pape; Mauro Schechter; Olivier Defawe; Stephen C De Rosa; David C Montefiori; Gary J Nabel; Lawrence Corey; Michael C Keefer; and the NIAID HIV Vaccine Trials Network","Aurum Institute for Health Research, Klerksdorp, South Africa; Centre for AIDS Programme of Research in South Africa (CAPRISA), University of Kwa-Zulu Natal, Durban, South Africa; Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH), Bethesda, Maryland, United States of America; Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, United States of America; Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa; Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa; Duke University Medical Center, Durham, North Carolina, United States of America; University of Alabama, Birmingham, Alabama, United States of America; Vanderbilt University, Nashville, Tennessee, United States of America; Harvard-Brigham and Womens Hospital, Boston, Massachusetts, United States of America; Alpert Medical School of Brown University and Miriam Hospital, Providence, Rhode Island, United States of America; Harvard Medical School- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America; University of Maryland, College Park, Maryland, United States of America; Centro de Referencia e Treinamento em DST/AIDS, Coordenacao dos Institutos de Pesquisa, San Paulo, Brazil; Epidemiology Research and Training Unit (ERTU), Kingston, Jamaica; Cornell-GHESKIO, Institut National de Laboratoire et de Recherches, Port au Prince, Haiti; Projeto Praça Onze, Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Duke Human Vaccine Institute, School of Medicine, Duke University, Durham, North Carolina, United States of America; Department of Medicine, University of Rochester School of Medicine & Dentistry, Rochester, New York, United States of America","Conceived and designed the experiments: GJC MCK CM EA JH BSG ZM DG OD SCD GDT DCM MJM GJN LC. Performed the experiments: GJC MCK GG L-GB PG SK LB ML RD WB AK JPF JP MS. Analyzed the data: GJC MCK ZM DG. Wrote the paper: GJC MCK CM EA JH BSG ZM DG OD SCD GDT DCM MJM GJN LC.","Dr. Nabel is named on patent applications for the DNA and adenovirus vector components of this vaccine concept (patents # E-173-2004/0-US-01, E-355-2003/0-US-01, and E-267-2004/0). This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors. None of the other authors have financial, personal, or professional interests that could be construed to have influenced the paper.","2011","08","Gavin J Churchyard","GJC",28,TRUE,15,14,4,15,TRUE,TRUE,TRUE,1,"28",TRUE
